From: Roche, Robert
To: Baldassano, Valli F.
CC: McCollum, Karen
Sent: 11/14/2007 1:12:38 PM

Subject: speech

Attachments: ROCHE POA SPEECH DALLAS 11 09 07.doc

Hello Valli

Here's 99% the speech I gave on Monday night.

A couple of last minute changes were made but they were not substantive.

Karen, thank you again for your draft.

Hope all goes well for you out there.

Bob

PLAINTIFFS TRIAL EXHIBIT
P-18763_00001

GOOD EVENING LADIES AND GENTLEMEN AND
WELCOME TO DALLAS, TEXAS. IT IS A GREAT
PLEASURE TO BE HERE WITH YOU TONIGHT AND A
REAL THRILL TO BE STANDING UP HERE IN FRONT OF
SO MANY SMART, TALENTED, DEDICATED, HARD
WORKING AND HONEST INDIVIDUALS. (PAUSE)

THERE'S GOING TO BE A LOT GOING ON THIS WEEK
BUT THE BIG REASON WE'RE ALL HERE IS TO
PREPARE FOR AND CELEBRATE THE LAUNCH OF
AMRIX...OUT LATEST ENTRY INTO THE CNS AND PAIN
MARKET. I THINK AMRIX IS GOING TO BE BIG, REALLY
BIG. YOU ARE GOING TO HEAR A TON ABOUT AMRIX
SO I WON'T SAY MUCH MORE THAN LET'S KNOCK THIS
BABY OUT OF THE PARK. GOOD LUCK WITH THIS
GREAT NEW PRODUCT! (PAUSE)

MAN...HAS THIS BEEN A CRAZY YEAR, OR WHAT?
THERE HAS BEEN SO MUCH GOING ON AT CEPHALON
THIS YEAR, BOTH IN THE HOME OFFICE AND WITH
YOU HERE IN THE SALES FORCE THAT ITS BEEN
ALMOST IMPOSSIBLE TO KEEP TRACK. SO, WHAT I
WANTED TO DO TONIGHT WAS JUST TAKE A FEW
STEPS BACK AND TRY TO FOCUS ON SOME OF THE
THINGS THAT ARE IMPORTANT...THE THINGS THAT
REALLY MATTER TO ALL OF US, PROFESSIONALLY
AND PERSONALLY.

TO DO THAT, I'M GOING TO REFLECT ON THREE
SIMPLE LITTLE THINGS...THE PAST, THE PRESENT
AND THE FUTURE. (PAUSE) DON'T WORRY, THIS
WON'T BE SOME BORING CEPHALON TRAVELOG BUT I
THINK IT IS REALLY INSTRUCTIVE TO HIGHLIGHT
SOME OF OUR GREAT ACCOMPISHMENTS AS WELL AS

SOME OF THE MISTAKES WE'VE MADE SO THAT WE CAN FIGURE OUT HOW TO BUILD ON THEM BOTH TO ENSURE OUR FUTURE SUCCESS. (PAUSE)

OK, THE PAST, THE PRESENT AND THE FUTURE...
THE PAST BECAUSE OF THE REMARKABLE JOURNEY
THAT DEFINES THIS COMPANY. THE PRESENT
BECAUSE OF THE CRITICAL TRANSITION PERIOD
WE'RE IN RIGHT NOW. AND THE FUTURE BECAUSE I
BELIEVE IT IS FAR BRIGHTER THAN ANYTHING WE
HAVE EXPERIENCED SO FAR.

SIMPLE RIGHT?? THIS SHOULDN'T TAKE MORE THAN A FEW HOURS...

LETS START WITH THE PAST...YOU *ALWAYS* START WITH THE PAST AND FOR CEPHALON, THE PAST IS REALLY AN INCREDIBLE STORY.

JUST TO REMIND YOU, CEPHALON CELEBRATED ITS

20TH ANNIVERSARY THIS PAST AUGUST AND MAJOR

MILESTONES ARE ALWAYS A GOOD TIME TO TAKE A

LOOK BACK AND REMIND OURSELVES OF WHAT WE

HAVE DONE. LET ME BRIEFLY SUMMARIZE THE LAST

20 YEARS AND MOST IMPORTANLY THE LAST 14

YEARS SINCE WE ESTABLISHED OUR COMMERICAL

ORGANIZATION.

OUR PAST IS FILLED WITH A LEGACY OF ACCOMPLISHMENT.

OF DISCOVERING AND DEVELOPING EXCITING NEW PRODUCTS

OF LAUNCHING AND MARKETING FIRST IN CLASS MEDICATIONS SUCH AS PROVIGIL AND ACTIQ.

OF POSITIONING OURSELVES AS LEADERS IN BOTH WAKEFULNESS AND PAIN MANAGEMENT,

OF SALES FORCE GROWTH AND EVOLUTION TO MAXIMIZE OUR EXCITING PRODUCT OPPORTUNITIES.

REMEMBER, IN 1999 WE LAUNCHED PROVIGIL WITH 45

REPS. 6 MONTHS LATER WE EXPANDED TO 85 THEN

125 THEN 200 THEN 250 THEN 500 AND BEYOND.

THESE 20 YEARS HAVE BEEN A TIME OF CREATING
AND NURTURING REMARKABLE PHYSICIAN AND
PATIENT LOYALTY TO OUR PRODUCTS

AND VERY IMPORTANTLY, THEY'VE BEEN A TIME OF PROVIDING UNINTERRUPTED VALUE TO ALL OF THE STAKEHOLDERS WHO TAKE AN INTEREST IN WHAT

WE DO – OUR CUSTOMERS, OUR SHARE HOLDERS, AND MOST IMPORTANTLY, OUR EMPLOYEES.

WE DID ALL THOSE THINGS FOR 2 REASONS, WE DID
THEM BECAUSE THEY WERE GOOD FOR THE
BUSINESS AND WE DID THEM BECAUSE THEY WERE
THE RIGHT THINGS TO DO. (PAUSE)

BUT WE ARE NO LONGER THAT SMALL STRUGGLING
BIOPHARMACEUTICAL COMPANY THAT HAD SUCH
GREAT POTENTIAL. WE ARE NO LONGER A NEW
COMMERICAL ENTITY THAT NEEDS TO GET SOME
SALES EXPERIENCE UNDER ITS BELT.

OH, NO...THIS YEAR, WE BECAME A FORTUNE 1000
COMPANY AND FOR THE FIRST TIME, CEPHALON WAS
LISTED AS ONE OF THE TOP 50 PHARMACEUTICAL
COMPANIES IN THE WORLD WITH REVENUES OF

NEARLY 2 BILLION DOLLARS. HERE'S NO DOUBT
ABOUT IT, WE ARE PLAYING IN THE MAJOR LEAGUES
NOW! THE LIGHTS ARE BRIGHTER, THE CHEERS ARE
LOUDER BUT THE SCRUTINY CAN BE BRUTAL AND
THE PRICE OF FAILURE IS VERY VERY HIGH.

WE ALL SAW THAT HAPPEN LAST WEEK.

OBVIOUSLY, THERE ARE PEOPLE OUT THERE WHO DON'T BELIEVE THAT THE SALES WE GENERATED OVER THE LAST 8 YEARS WERE BASED ON INTEGRITY. THEY BELIEVE THAT OUR PERFORMANCE WAS BASED ON SOMETHING LESS THAN HARD WORK AND HONEST EFFORT. THAT WE TOOK THE EASY WAY INSTEAD OF THE RIGHT WAY.

AS A RESULT WE FOUND OURSELVES DEFENDING
OUR PROMOTIONAL PRACTICES AND SADLY, IT

TURNED OUT THAT WE DEFINITELY DID SOME THINGS WRONG.

WHEN WE MET THIS PAST JUNE, I FELT OBLIGATED TO APOLOGIZE TO ERIC SEIGEL, OUR FORMER CHIEF COMPLIANCE OFFICER BECAUSE I FELT I'D LET HIM DOWN.

TODAY, I WANT TO APOLOGIZE TO ALL OF YOU FOR EXACTLY THE SAME REASON.

I KNOW THAT YOU GUYS HAVE FELT UNDER SIEGE
FOR THE LAST 6 MONTHS AND THAT YOU'VE FELT
LIKE YOU ARE THE SCAPEGOATS FOR ALL OF THE
PROBLEMS WE HAVE BEEN EXPERIENCING. THAT YOU
AND YOU ALONE WERE BEING BLAMED FOR
EVERYTHING BAD THAT'S HAPPENED AND GETTING
NONE OF THE CREDIT FOR ANYTHING GOOD.

WELL, IF THERE'S ONE THING I CAN ACCOMPLISH, **ONE** THING AS I SPEAK TO YOU TONIGHT, IT WOULD BE TO LET YOU KNOW THAT FRANK BALDINO, OUR BOARD OF DIRECTORS AND THE ENTIRE LEADERSHIP TEAM OF THIS COMPANY INCLUDING ME. UNDERSTAND THAT WHAT HAPPENED TO US WAS **NOT** JUST YOUR FAULT, THAT THE FINE WE'RE GOING TO PAY IS **NOT** JUST YOUR FAULT. THAT THE CRIMINAL MISDAMEANOR PLEA IS **NOT** JUST YOUR FAULT. NO, WE UNDERSTAND THAT THESE THINGS WERE NOT **YOUR** FAULT....THEY WERE OUR FAULT.....SALES, MARKETING, CLINICAL, REGULATORY AFFAIRS, BOB ROCHE, THE EXECUTIVE COMMITTEE. ALL OF US.

I, AND THE OTHER OFFICERS OF THIS CORPORATION,

TAKE FULL RESPONSIBILITY FOR THE BEHAVIORS OF

OUR EMPLOYEES, AND IN THIS CASE, WE ARE ALL AT FAULT FOR NOT GIVING YOU ALL OF THE NECESSARY SUPPORT, AND TOOLS, AND TRAINING AND OVERSIGHT THAT YOU NEEDED TO BE BOTH EFFECTIVE AND COMPLIANT... ALL THE TIME. (PAUSE)

WE ASKED YOU TO TELL A STORY ABOUT OUR
PRODUCTS THAT TURNED OUT TO BE TOO COMPLEX,
WE GAVE YOU TOO MUCH LEEWAY TO DEFINE YOUR
OWN MESSAGE AND NOT ENOUGH GUIDELINES AND
TRAINING ON WHAT YOU COULD DO AND WHAT YOU
COULD NOT DO.

WE SHOULD NOT LOSE SIGHT OF THE FACT THAT

SOME OF THE BEHAVIORS WHICH SURFACED DURING

THE INVESTIGATION WERE NOTHING MORE OR LESS

THAN STUPID BLATANT EXAMPLES OF OFF-LABEL

PROMOTION AND THOSE WERE THE LAST STRAW BUT

IN MOST CASES, THERE WAS A LOT OF GREY AROUND THE EDGES AND IF YOU'LL REMEMBER, AROUND THE EDGES WAS JUST WHERE WE WANTED YOU TO BE.

LAST WEEK YOU LEARNED THAT WE AGREED TO PAY
A 425 MILLION DOLLAR FINE TO SETTLE THE FEDERAL
INVESTIGATION THAT HAS BEEN UNDERWAY FOR AT
LEAST THE LAST 5 YEARS.

425 MILLION. (PAUSE) THERE'S OBVIOUSLY A LOT OF BAD NEWS ABOUT A FINE THAT BIG. YOU KNOW, THE WORST OF IT FOR ME WAS HAVING TO CALL MY MOM AND TELL HER, IN THE IMMORTAL WORDS OF OUR FORMER AND DISGRACED PRESIDENT, RICHARD NIXON, "I AM NOT A CROOK". I'LL BET THAT SOME OF YOU GUYS MADE CALLS LIKE THAT YOURSELVES.

ALSO, THAT'S 425 MILLION THAT WE NOW DON'T HAVE TO BUY A NEW PRODUCT OR COMPANY.

425 MILLION THAT WE CANNOT INVEST IN EXCITING RESEARCH AND DEVELOPMENT PROJECTS.

425 MILLION THAT'S NOT IN THE BANK EARNING A HANDSOME RETURN.

425 MILLION DOLLARS, MY *GOD* THAT'S A LOT OF MONEY. THINK OF ALL THE GOOD WE COULD HAVE DONE WITH IT BUT NOOO, WE SCREWED UP AND NOW WE HAVE TO PAY IT TO THE FEDERAL GOVERNMENT.

AT LEAST THERE'S A TINY BRIGHT SIDE TO THIS.

(PAUSE) THE ONLY GOOD NEWS I CAN SEE IS THAT

WE CAN AFFORD TO PAY THIS FINE OUT OF OUR

CASH RESERVES AND NOT BE CRIPPLED AS A

FINANCIAL ENTITY. WHAT WE *CANNOT* AFFORD IS TO CONTINUE TO PUT OUR COMPANY AT RISK OR TO EVER BE IN THIS POSITION AGAIN.

EARLY NEXT YEAR WE EXPECT TO HAVE A CORPORATE INTEGRITY AGREEMENT FINALIZED AND WITH THAT STEP, ALL ASPECTS OF THE INVESTIGATON WILL BE CLOSED. I CAN'T TELL YOU TODAY WHAT EVERY ELEMENT OF THAT AGREEMENT WILL ENTAIL. SOME OF YOU MAY HAVE WORKED UNDER CIAS BEFORE AND HAVE MORE EXPERIENCE THAN ME. OUR NEW COMPLIANCE OFFICER, VALLI BALDASSANO – WHO IS JOINING US LATER THIS WEEK BELIEVES THAT WE HAVE ALREADY MADE MANY OF THE CHANGES THAT WILL BE LAID OUT IN THE FINAL AGREEMENT. THAT'S A GOOD THING. (PAUSE)

SHE IS ALSO ADAMANT THAT THE APPROACH WE TAKE IS **NOT** TO CATCH, BUT TO COACH. DID YOU GET THAT, COACH... NOT CATCH. VALLI HAS ALSO MADE IT CLEAR TO ME THAT AT LEAST ONE THING WE'VE RECENTLY IMPLEMENTED HAS TO CHANGE. SHE DOES NOT LIKE THE SALES FORCE AUDIT PROCESS. THESE VERBATIMS THAT WE ARE GATHERING, AND HAS SAID THAT IT WILL BE DRAMATICALLY CHANGED AND **NOT** BE USED AS A STAND ALONE PUNITIVE DEVICE. THE "3 STRIKES AND YOU'RE OUT" IDEA WHICH WAS RECOMMENDED BY HER PREDECESSORS WILL GO AWAY. REMEMBER, ITS NOT ABOUT CATCHING, ITS ABOUT COACHING.

I KNOW THAT YOU LEFT THE MEETING IN

PHILADELPHIA CONFUSED AND EVEN FEARFUL

ABOUT WHAT YOU COULD OR COULD NOT DO AND

WHAT THE COMPANY WOULD DO TO YOU IF YOU

MADE A MISTAKE. IN THE AFTERMATH OF THAT

MEETING AND OVER THE LAST FEW MONTHS YOU DID

THE NATURAL THING AND DIALED YOUR

PROMOTIONAL APPROACH WAY BACK. (PAUSE)

THERE'S A FINE LINE BETWEEN WHAT'S ACCEPTABLE PROMOTION AND WHAT IS NOT BUT RIGHT NOW, I GET THE IDEA THAT WE CAN'T EVEN SEE THAT LINE WE'RE SO FAR BACK FROM IT. AS A RESULT OF THAT SALES HAVE SUFFERED. BOTH PROVIGIL AND FENTORA ARE TRENDING DOWNWARDS AND WE HAVE JUST *GOT* TO TURN THAT AROUND.

WHAT I WANT TO ASK YOU TO DO NOW IS <u>GET BACK</u>

<u>INTO THE GAME</u>, IN A BIG WAY. TAKE THE MATERIALS

AND MESSAGES YOU HAVE BEEN PROVIDED FOR

PROVIGIL AND FENTORA AND RECOMMIT TO SELLING

THESE PRODUCTS AGGRESSIVELY, EFFECTIVELY AND

PROPERLY. IF YOU DO THOSE 3 THINGS WE CAN ALL BE SUCCESSFUL.

TODAY, WE ARE MAKING PLANS FOR THE FUTURE.

PLANS THAT INCLUDE BRINGING NEW ENERGY TO

SELLING RIGHT. PLANS THAT WILL REVITALIZE THE

GROWTH FOR OUR FLAGSHIP PRODUCT, PROVIGIL.

LAST THURSDAY, WE REPORTED THAT SALES OF
PROVIGIL GREW 9 PERCENT OVER QUARTER 3 OF
2006 AND I BELIEVE THERE IS STILL ROOM FOR
SIGNIFICANT GROWTH IN THE YEARS AHEAD.

(PAUSE) THE PROVIGIL MARKETING TEAM IS
PLANNING SOME EXCITING INITIATIVES THAT WE WILL
IMPLEMENT EARLY NEXT YEAR AND YOU WILL BE
LEARNING MORE ABOUT THE TOOLS WE ARE
CREATING TO FUEL THE MOMENTUM WE ARE SEEING
BUILD IN EXCESSIVE SLEEPINESS IN OBSTRUCTIVE

SLEEP APNEA. YOU'LL ALSO HEAR MORE ABOUT OUR PLANS FOR PHASE FOUR STUDIES THAT SUPPORT THAT FOCUS AND THAT MAY ALLOW US TO EXTEND OUR PROMOTIONAL MESSAGES.

WE ALSO MUST MAKE THE MOST OF FENTORA

TODAY, WHILE PREPARING FOR A BROADER

INDICATION IN THE FUTURE. AS EXPECTED, WE ARE

CONTINUING TO SEE EROSION OF SALES OF ACTIQ

AND THEREFORE, THIS QUARTER WE REPORTED A 33

PERCENT DECREASE IN OUR PAIN FRANCHISE SALES.

FENTORA HAS TAKEN SOME HITS IN THE LAST FEW
WEEKS WITH THE DEAR DR LETTER AND WIDELY
PUBLICISED CONCERNS ABOUT APPROPRIATE USE
AND SAFETY BUT WE *MUST* KEEP OUR FOCUS ON
THIS KEY BRAND. I AM COUNTING ON YOU GUYS ON
THE PAIN CARE TEAM TO GET FENTORA BACK ON THE

RIGHT TRACK AND BACK ON A GROWTH TREND THAT WILL TAKE US CLOSE TO THE 200 MILLION DOLLAR MARK NEXT YEAR.

REMEMBER THAT THIS IS THE LAUNCH MEETING FOR AMRIX AND EVERYBODY IN THIS ROOM WILL BE CRITICAL TO THIS GREAT NEW PRODUCT'S SUCCESS. WE MUST ALL WORK TOGETHER TO MAXIMIZE THE LAUNCH OF AMRIX.

THINK ABOUT IT, A PRODUCT THAT WE ACTUALLY
EXPECT DOCTORS WILL USE FOR THE INDICATIONS
WE CAN PROMOTE...WHAT A WONDERFUL CONCEPT.

AMRIX HAS A BROAD LABEL THAT WILL ALLOW US TO REALLY MAXIMIZE OUR SELLING EFFORT. IT'S GOING TO GROW INTO A MAJOR PRODUCT IN ITS OWN RIGHT AND HELP US BRIDGE THE COMPANY THROUGH THE

LAUNCHES OF TREANDA, THE BROADER FENTORA

LABEL AND THE LAUNCH OF NUVIGIL IN 2010. (PAUSE)

THE IMPORTANT MESSAGE FOR YOU TO

UNDERSTAND TODAY IS THAT YOUR COMPANY AND

THE OTHER 2500 EMPLOYEES NOT SITTING IN THIS

ROOM TONIGHT ARE COUNTING ON YOU, EVERY

SINGLE ONE OF YOU TO DO YOUR JOBS WELL AND TO

DO THEM RIGHT TO GET PROVIGIL AND FENTORA

BACK ON TRACK AND TO MAKE AMRIX A BIG

SUCCESS. (PAUSE)

I'VE BEEN AROUND YOU GUYS LONG ENOUGH TO
KNOW THAT THIS IS A CHALLENGE YOU CAN HANDLE.
(PAUSE)

THERE IS NO DOUBT THAT THIS YEAR HAS ALREADY
BEEN ONE OF BOTH CHALLENGE AND CHANGE FOR

CEPHALON AND THERE'S MORE TO COME. WE CAN'T AND WON'T RUN FROM THAT CHANGE. AND HERE'S WHERE THE RELEVANCE OF OUR PAST PAYS OFF—AT CEPHALON, CHANGE IS IN OUR DNA.

EVERY YEAR AT CEPHALON LOOKS DIFFERENT FROM
THE YEAR BEFORE, IT IS AS IF WE ARE CONSTANTLY
RE-INVENTING OURSELVES. (PAUSE) THAT IS WHAT
IT MEANS TO EVOLVE. IN ORDER TO MOVE
FORWARD; IN ORDER TO BE SUCCESSFUL, *WE* MUST
CHANGE AND EVOLVE.

I RECOGNIZE THAT AT FIRST, CHANGE TENDS TO

MAKE MOST PEOPLE, INCLUDING ME, FEEL NERVOUS

AND UNCOMFORTABLE. (PAUSE)

THAT BEING THE CASE, I'D LIKE TO SHARE ONE PERSPECTIVE ON CHANGE:

CHANGE IS THE LAW OF LIFE. AND THOSE WHO LOOK
ONLY TO THE PAST OR PRESENT ARE CERTAIN TO
MISS THE FUTURE. (PAUSE)

THOSE ARE THE WORDS OF ONE OF THIS COUNTRY'S MOST ADMIRED LEADERS- JOHN F. KENNEDY- AND COULDN'T BE BETTER SUITED FOR US TODAY AS WE LOOK TO CREATE *OUR* OWN FUTURE. LET ME SAY THAT JUST ONE MORE TIME (slowly): CHANGE IS THE LAW OF LIFE. AND THOSE WHO LOOK ONLY TO THE PAST OR PRESENT ARE CERTAIN TO MISS THE FUTURE.

AT THIS POINT IN OUR HISTORY WE MUST ALL BE FORWARD LOOKING IN ORDER TO SUCCEED WITHIN THIS DYNAMIC INDUSTRY AND AS WE LOOK TO OUR

FUTURE, THERE ARE **MANY** NEW OPPORTUNITIES IN FRONT OF US.

LAST WEEK, WE PROVIDED SALES GUIDANCE THAT INCLUDES A \$100 MILLION GROWTH TARGET FOR 2008. THAT'S ONLY ABOUT 8% TOPLINE GROWTH, PRETTY MODEST BY CEPHALON STANDARDS BUT REASONABLE UNDER THE CIRCUMSTANCES.

HOPEFULLY WE CAN DO EVEN BETTER.

LAST WEEK WE TOLD THE STREET THAT WE EXPECT
TO HAVE A VERY SUCCESSFUL LAUNCH OF AMRIX.
AND THIS WEEK, THE SALES AND MARKETING
LEADERSHIP TEAM WILL ARM YOU WITH ALL OF THE
TOOLS YOU NEED TO MAKE THIS HAPPEN. OUR ONGOING EXPANSION INTO THE PRIMARY CARE MARKET
HAS PREPARED US FOR THIS OPPORTUNITY AND
WITH THE RIGHT MESSAGE, THE RIGHT SUPPORT AND

YOUR FOCUS ON DOING THINGS THE RIGHT WAY, I AM CONFIDENT WE WILL ONCE AGAIN SHOW EVERYONE, BOTH INSIDE *AND* OUTSIDE OF THIS COMPANY, WHAT WE ARE MADE OF.

AFTER AMRIX, OUR NEXT OPPORTUNITY WILL BE THE LAUNCH OF TREANDA FOR CHRONIC LYMPHOCYTIC LEUKEMIA CLL, AND CLOSELY BEHIND IT, FOR NON HODGKINS LYMPHOMA NHL. WE JUST ANNOUNCED SOME VERY POWERFUL NEW DATA AND TREANDA IS GENERATING A TON OF EXCITEMENT IN THE ONCOLOGY COMMUNITY. WE ARE EXPECTING TO LAUNCH TREANDA BY MID-YEAR IN 2008 AND ARE IN THE PROCESS OF BUILDING UP OUR ONCOLOGY TEAM TODAY INTO A FULLY FLEDGED BUSINESS UNIT. (PAUSE)

PROVIGIL, FENTORA, TREANDA AND AMRIX. THAT'S WHAT WE'VE GOT. THESE PRODUCTS MUST ALL CONTRIBUTE AS DRIVERS FOR SALES GROWTH NEXT YEAR. AND AS WE LOOK AT OUR PLANS WE KNOW OUR COMMERICAL EXECUTION MUST BE OUTSTANDING IF WE ARE TO REACH OUR GOALS. FOR THAT REASON, WE MUST BOTH FOCUS OUR EFFORTS AND APPROPRIATELY RESOURCE THESE PRODUCTS FOR SUCCESS. AND IT BEARS REPEATING THAT WE MUST ACCOMPLISH THIS WHILE STAYING WITHIN THE BOUNDARY OF THE LETTER AND SPIRIT OF THE LAW.

WE NEED TO LEARN FROM OUR EXPERIENCES, BOTH POSITIVE AND NEGATIVE AND AT THIS TIME, I AM ASKING ALL OF YOU TO JOIN WITH ME AND MARCH FORWARD TOGETHER USING THESE EXPERIENCES TO PAVE A SOLID, BRIGHT FUTURE FOR *CEPHALON*,

AND FOR EACH AND EVERY ONE OF US INDIVIDUALLY.
(PAUSE)

THE COMPANY IS CHANGING AND AS OF TODAY, NOVEMBER 12TH, WE ARE STILL IN THE PROCESS OF DEFINING EXACTLY WHAT OUR COMMERCIAL ORGANIZATION NEEDS TO LOOK LIKE AS WE ENTER 2008. THERE IS GOING TO BE SOME MORE REORGANIZATION AS WE OPTIMIZE TERRITORIAL ALIGNMENT AROUND AMRIX AND THIS WILL EFFECT BOTH THE CNS AND PAIN CARE TEAMS, I AM SORRY THIS IS TAKING AS LONG AS IT IS, BUT WITH SOME OF THE OTHER ISSUES THAT WERE HANGING OVER US, WE JUST **COULD NOT** MOVE THE PROCESS ALONG ANY FASTER. I CAN ASSURE YOU NOW THAT BY THE FIRST WEEK OF DECEMBER WE WILL HAVE COMMUNICATED WITH EVERY SINGLE ONE OF YOU

AND YOU WILL KNOW PRECISELY WHERE YOU STAND MOVING FORWARD. (PAUSE)

MOVING FORWARD, THAT'S WHAT WE NEED TO DO.

GET THIS YEAR BEHIND US AND GET BACK TO DOING

THE THINGS WE DO REALLY WELL. THERE IS NO

DOUBT IN MY MIND THAT WE CAN DO THAT AND BE AS

SUCCESSFUL AS WE'VE EVER BEEN, BUT WE'VE GOT

TO DO TWO THINGS.

WE'VE GOT TO BE WILLING TO LEARN FROM OUR
ACCOMPLISHMENTS AND MISTAKES AND
WE'VE GOT TO HAVE THE COURAGE TO CHANGE AND
EVOLVE WITHIN THE ENVIRONMENT IN WHICH WE
WORK SO THAT WE CAN BE AHEAD OF THE CURVE IN
EVERYTHING WE DO.

CEPHALON IS A GREAT COMPANY WITH UNIQUE
PRODUCTS, A BRIGHT, SOLID FUTURE, AND THE BEST
EMPLOYEES, ESPECIALY THE BEST SALES AND
MARKETING TEAM IN THE INDUSTRY.

TOGETHER WE CAN BRING CEPHALON TO WHERE IT NEEDS TO BE FROM A BUSINESS PERSPECTIVE AND DO SO WITH **PRIDE** AND INTEGRITY.

I PROMISE THAT YOU CAN COUNT ON ME AND YOUR SALES LEADERSHIP AS WELL AS THE ENTIRE MANAGEMENT TEAM TO SEEK OUT AND MAXIMIZE NEW OPPORTUNITIES FOR YOU AND FOR THIS COMPANY.

TONIGHT, I'M ASKING YOU TO RENEW **YOUR**COMMITMENT AND DEDICATION TO HOLDING UP **YOUR** PART OF THE BARGAIN, TO GETTING OUT

THERE AND WORKING YOUR BUTTS OFF TO MAKE SURE THIS BUSINESS REMAINS SUCCESSFUL.

WE ARE NOT THE FIRST OR THE LAST ORGANIZATION
THAT FINDS ITSELF IN THE MIDST OF TRANSITION AND
CHANGE AS WE GROW AND LEARN.

DON'T FIGHT THE CHANGE, EMBRACE IT! IF YOU DO,
YOU CAN ACHIEVE THINGS THAT MAY NOT HAVE
SEEMED POSSIBLE EVEN A FEW SHORT MONTHS
AGO. DO IT AND BUILD THE FOUNDATION FOR A SOLID
FUTURE FOR CEPHALON, AND FOR YOURSELVES AS
PEOPLE AND PROFESSIONALS. (PAUSE)

YEP, CEPHALON'S 20 YEARS OLD. THAT'S AMAZING TO ME AND WHAT'S EVEN MORE AMAZING IS THAT I'VE BEEN HERE FOR 14 OF THOSE YEARS. WE'VE DONE **SO MUCH** IN THESE FIRST TWO DECADES BUT I

REALLY BELIEVE THAT TWENTY YEARS FROM NOW,
WE WILL LOOK BACK AND BE PROUDER STILL OF
WHAT WE ARE ABOUT TO ACCOMPLISH, PROUD THAT
WE TOOK CEPHALON TO PLACES THAT TODAY WE
CAN'T EVEN IMAGINE.

I CAN TELL YOU, *I'M* LOOKING FORWARD TO THAT
JOURNEY AND I'M LOOKING FORWARD TO MAKING IT
WITH *YOU*.

THANKS FOR YOUR ATTENTION THIS EVENING AND
THANKS FOR EVERYTHING **YOU** DO, **EVERY DAY**, TO
MAKE THIS COMPANY GREAT.